In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain

BMC Research Notes

R Nalini Prasad¹  Syed Hussain Basha¹ 

[1] Dept. of Biotechnology, REVA Institute of Science and Management, Yelahanka, Bangalore 560 064, India

关键词: Docking analysis;    Neuraminidase;    H1N1;    Oseltamivir;    Pleconaril;   

Others  :  1166654
DOI  :  10.1186/1756-0500-5-105

 received in 2011-09-06, accepted in 2012-02-17,  发布年份 2012

【 摘 要 】

Background

Neuraminidase (NA) is a prominent surface antigen of Influenza viruses, which helps in release of viruses from the host cells after replication. Anti influenza drugs such as Oseltamivir target a highly conserved active site of NA, which comprises of 8 functional residues (R118, D151, R152, R224, E276, R292, R371 and Y406) to restrict viral release from host cells, thus inhibiting its ability to cleave sialic acid residues on the cell membrane. Reports on the emergence of Oseltamivir resistant strains of H1N1 Influenza virus necessitated a search for alternative drug candidates. Pleconaril is a novel antiviral drug being developed by Schering-Plough to treat Picornaviridae infections, and is in its late clinical trials stage. Since, Pleconaril was designed to bind the highly conserved hydrophobic binding site on VP1 protein of Picorna viruses, the ability of Pleconaril and its novel substituted derivatives to bind highly conserved hydrophobic active site of H1N1 Neuraminidase, targeting which oseltamivir has been designed was investigated.

Result

310 novel substituted variants of Pleconaril were designed using Chemsketch software and docked into the highly conserved active site of NA using arguslab software. 198 out of 310 Pleconaril variants analyzed for docking with NA active site were proven effective, based on their free binding energy.

Conclusion

Pleconaril variants with F, Cl, Br, CH3, OH and aromatic ring substitutions were shown to be effective alternatives to Oseltamivir as anti influenza drugs.

【 授权许可】

   
2012 Basha et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Noble D, Colatsky TJ: A return to rational drug discovery: computer-based models of cells, organs and systems in drug target identification. Emerging therapeutic targets 2000, 4:39-49.
• [2]Ekins S, Mestres J, Testa B: In-silico pharmacology for drug discovery: Applications to targets and beyond. Br J Pharmacol 2007, 152:21-37.
• [3]John Cartar B, Venetia Saunders A: Virology-principles and applications. First edition. India: John Wiley and sons limited publications; 2007:317-322.
• [4]Von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
• [5]Aoki FY, Boivin G, Roberts NA: Influenza virus susceptibility and resistance to Oseltamivir. Anti viral Therapy 2007, 12:603-616.
• [6]Magden J, Kääriäinen L, Ahola T: Inhibitors of virus replication:recent developments and prospects. Appl Microbiol Biotechnol 2005, 66:612-621.
• [7]Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295AM2) ClinicalTrials.gov. U.S. National Institutes of Health; 2007. Retrieved 2011-12-26
• [8]Florea N, Maglio D, Nicolau D: Pleconaril, a novel antipicornaviral agent. Pharmacotherapy 2003, 23(3):339-48.
• [9]Kitchen DB, Decornez H, Furr JR, Bajorath J: Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Review Drug Discovery 2004, 3:935-949.
• [10]Irawin Kuntz D, Elaine Meng C, Shoichet Brain K: Structure-Based Molecular Design. Accounts of Chemical research 1994, 27(5):117-123.
• [11]Jain AN: Scoring functions for protein-ligand docking. Curr Protein Pept Sci 2006, 7(5):407-20.
• [12]Shoichet BK, Kuntz ID, Bodian DL: Molecular docking using shape descriptors. J Comput Chem 2004, 13(3):380-397.
• [13]Bernstein FC, Koetzle TF, Williams GJ, Meyer EE Jr, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M: The Protein Data Bank: A Computer-based Archival File For Macromolecular Structures. J Mol Biol 1977, 112:535.
• [14]Xiaojin Xu, Xueyong Zhu, Raymond Dwek A, James Stevens, Ian Wilson A: Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase. J Virol 2008, 82(21):10493-10501.
• [15][http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=65028&loc=ec_rcs ] webcite National Center for Biotechnology Information: PubChem Compound Database; CID = 65028, (accessed Dec. 26, 2011)
• [16][http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=1684&loc=ec_rcs] webcite National Center for Biotechnology Information: PubChem Compound Database; CID = 1684, (accessed Dec. 26, 2011)
• [17]Bolton E, Wang Y, Thiessen PA, Bryant SH: PubChem: Integrated Platform of Small Molecules and Biological Activities. In Chapter 12 IN Annual Reports in Computational Chemistry. Volume 4. American Chemical Society, Washington, DC; 2008.
• [18]2007. ACD/ChemSketch Freeware, version 11.01, Advanced Chemistry Development, Inc., Toronto, ON, Canada, www.acdlabs.com webcite
• [19]Mark A[http://www.arguslab.com] webciteThompson, ArgusLab 4.0.1, Planaria Software LLC, Seattle, WA;
• [20]Rappe AK, Casewit CJ, Colwell KS, Goddard WA, Skiff WM: UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J Am Chem Soc 1992, 114:10024-10035.
• [21]Rappe AK, Colwell KS, Casewit CJ: Application of a Universal force field to metal complexes. Inorg Chem 1993, 32:3438-3450.
• [22]Rappe AK, Goddard WA: Charge Equilibration for molecular dyanamics simulations. J Phys Chem 1991, 95:3358-3363.
• [23]Casewit CJ, Colwell KS, Rappe' AK: Application of a universal force field to organic molecules. J Am Chem Soc 1992, 114:10035-10046.
• [24]Casewit CJ, Colwell KS, Rappe' AK: Application of a universal force field to main group compounds. J Am Chem Soc 1992, 114:10046-10053.
• [25][http://accelrys.com/products/discovery-studio/visualization-download.php] webcite Accelrys Software Inc., 2011, Discovery studio Visualizer 3.0,